Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Sep 2025 value amounting to $66.4 million.

  • Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) rose 8.65% to $66.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.4 million, marking a year-over-year increase of 8.65%. This contributed to the annual value of $61.5 million for FY2024, which is 3.99% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $66.4 million for Q3 2025, which was up 4.40% from $63.6 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $66.4 million during Q3 2025, with a 5-year trough of $50.2 million in Q1 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $61.0 million in 2024 and averaged $60.6 million.
  • Data for Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY rose of 13.90% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $50.3 million in 2021, then rose by 12.10% to $56.3 million in 2022, then grew by 4.88% to $59.1 million in 2023, then climbed by 3.99% to $61.5 million in 2024, then climbed by 8.65% to $66.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $66.4 million for Q3 2025, versus $63.6 million for Q2 2025 and $63.2 million for Q1 2025.